About 291,410 results

Will ‘gold card’ legislation and others rein in prior authorizations?
Madelaine (Mattie) Feldman, MD

May 23rd, 2022 - I live in New Orleans and recently became aware of a piece of state legislation that would create a “gold card” system for prior authorizations in Louisiana. Before delving into what is a gold card and how it works, let’s take a look at the evolution of prior authorizations (PAs).

Doxycycline bests azithromycin for anorectal chlamydia in women
Marilynn Larkin

May 23rd, 2022 - NEW YORK (Reuters) – A one-week course of doxycycline was superior to a single dose of azithromycin in women with concurrent vaginal and anorectal chlamydia infection in an unblinded randomized controlled trial, mirroring previous results in men. Researchers suggest that doxycycline should be the first-line therapy for chlamydia infection in women.

PI-based DAAs appear safe in decompensated patients
Jim Kling

May 22nd, 2022 - SAN DIEGO – An analysis of a large, international cohort suggests that treatment with protease-inhibitor (PI)–based direct-acting antivirals (DAAs) may be safe for patients with hepatitis C virus (HCV) with cirrhosis and early-stage liver decompensation. The study relied on data from the REAL-C registry, including 935 patients treated with oral DAAs at 27 centers in the U.

Treatment for alcohol abuse reduces hepatitis readmission
Laird Harrison

May 22nd, 2022 - SAN DIEGO – Treating people with alcoholic hepatitis for alcohol abuse may reduce their risk of hospital readmission, researchers reported. In a retrospective analysis of nationwide data, 7.

Voice-Analysis App Promising as Early Warning System for Heart Failure Decompensation

May 21st, 2022 - A voice can carry a long distance, but in patients with heart failure (HF) a voice can also carry otherwise hidden signs useful for predicting short-term risk for worsening disease, even acute decompensation. Potentially, it only has to reach a smartphone to do it, suggests a preliminary study of a mobile app designed to alert patients and clinicians to such looming HF events, if possible in ti...

Air pollution linked to deadly heart rhythm disorder

May 21st, 2022 - Madrid, Spain – 21 May 2022: Life-threatening arrhythmias are more common on days with highly polluted air, according to research presented today at Heart Failure 2022, a scientific congress of the European Society of Cardiology (ESC).1 The study was conducted in patients with an implantable cardioverter defibrillator (ICD), enabling the authors to track the occurrence of arrhythmias and delive...

Gender Affirming Hormone Therapy has a positive impact on well-being

May 21st, 2022 - New evidence shows that people who have undergone Gender Affirming Hormone Therapy report high grades of satisfaction with both the physical and psychological effects. A new study on this topic, carried out by researchers in Portugal, will be presented today (21 May 2022) at the 24th European Congress of Endocrinology in Milan, Italy. Gender Affirming Hormone Therapy (GAHT) aims to align the ch...

The anxious patient needs psychosomatic primary care
Horst Gross, MD

May 20th, 2022 - A balance between fear and relaxation is normal. However, mental dispositions and the continuous influence of environmental stimuli can disrupt this balance.

Persistent dry cough

May 20th, 2022 - On the basis of the patient's presentation, history, and imaging results, the likely diagnosis is metastatic small cell lung cancer (SCLC). Most patients with SCLC present with hematogenous metastases; only about one third present with limited disease confined to the chest that is amenable to multimodal therapy.

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sam...
MedWatch; FDA

May 20th, 2022 - Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were plac...

SCAI issues guidelines for PFO management, makes case for expansion
Richard Mark Kirkner

May 20th, 2022 - The first-ever guidelines for interventional cardiologists using percutaneous patent foramen ovale closure recommend expanding the use of the procedure beyond the Food and Drug Administration–approved indication following PFO-associated ischemic stroke, adding clarification about the use of PFO with anticoagulation and hedging against abuse and overuse of the procedure, said the chair of the gu.

Venous thromboembolism: Less recurrencies with low-dose apixaban compared to discontinuation of the anticoagulant after negative D-dimer

May 20th, 2022 - Bologna 8 April 2022 - Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, instead of continuing with low-dose anticoagulant (apixaban). These are the results of the APIDULCIS study presented at the 6th Conference of the Arianna Anticoagulation Found...

Long term use of clopidogrel monotherapy associated with lower patient risk compared to aspirin monotherapy

May 20th, 2022 - ATLANTA, GA (May 20, 2022) – Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin monotherapy beyond 12 months after PCI in high-risk patients during the chronic maintenance period. This study found that clopidogrel monotherapy was associated with reduced risk of net adverse clinical events (NACE; all-cause death, MI, stent thrombosis, stroke, or ...

Study identifies new molecular target for cancer therapy

May 20th, 2022 - COLUMBUS, Ohio – Researchers with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) have identified a new molecular drug target that could result in new cancer drugs with fewer side effects. Previous studies have shown that vascular endothelial growth factor-A (VEGF-A) – a potent cytokine (signaling ...

Scientists gain ground on rare congenital neurological disorder

May 20th, 2022 - Two recent discoveries co-led by scientists at Cedars-Sinai may help lead to new ways to treat patients with Allan-Herndon-Dudley syndrome (AHDS), a brain development disorder that causes severe intellectual disability and problems with movement. In the first study, published in the peer-reviewed journal Thyroid, scientists at Cedars-Sinai and at the University of Chicago identified a gene ther...

A pioneering study discovers an underlying cause for infantile spasms and points to a novel therapy

May 20th, 2022 - Infantile spasm (IS) is a severe epileptic syndrome of infancy and accounts for 50% of all epilepsy cases that occur in babies during the first year of life. Current treatment options for this disorder are limited and most affected infants grow up to have developmental delays, intellectual disabilities and other types of severe epilepsy. A groundbreaking study, conducted in the laboratory of Dr...

No-implant interatrial shunt device to treat heart failure patients reveals promising multi-center clinical data

May 20th, 2022 - ATLANTA, GA (May 20, 2022) – Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2022 Scientific Sessions. This multi-center evaluation across three trial programs (AL...

New clues in fight against lethal bacteria

May 20th, 2022 - New research from The Australian National University (ANU) could lead to better treatment options for a rare but very lethal type of bacterial infection. Professor Si Ming Man and his team say their latest research focuses on the family of bacteria that causes things like gangrene, sepsis and tetanus. “While we understand a select few members of this family of bacteria, we were interested in wh...

Risk of alcohol-associated liver disease after medical therapy for alcohol use disorder

May 20th, 2022 - About The Study: Patients with alcohol use disorder who received medical addiction therapy had a significantly lower risk of developing alcohol-associated liver disease, according to the results of this study that included 9,635 patients. Authors: Jay Luther, M.D., of Massachusetts General Hospital in Boston, is the corresponding author. To access the embargoed study: Visit our For The Media we...

Allergen-Specific Immunotherapy During Pregnancy Appears Safe for Babies

May 20th, 2022 - NEW YORK (Reuters Health) - Maintaining allergen-specific immunotherapy (AIT) during pregnancy shows no evidence of raising the risk of congenital malformations or other adverse pregnancy outcomes, according to a nationwide study from Sweden. Although a few earlier studies evaluating AIT in pregnant women have come to similar conclusions, they were small "and guidelines continue to recommend ag...